UBS Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-20,385
| Closed | -$26K | – | 10534 |
|
|
2023
Q3 | $26K | Sell |
20,385
-6,183
| -23% | -$5.4K | ﹤0.01% | 6668 |
|
|
2023
Q2 | $8.66K | Sell |
26,568
-3,718
| -12% | -$1.33K | ﹤0.01% | 7221 |
|
|
2023
Q1 | $13K | Sell |
30,286
-11,734
| -28% | -$6.18K | ﹤0.01% | 7419 |
|
|
2022
Q4 | $22.3K | Buy |
42,020
+15,130
| +56% | +$9.6K | ﹤0.01% | 7543 |
|
|
2022
Q3 | $20K | Buy |
26,890
+1,988
| +8% | +$2.26K | ﹤0.01% | 7436 |
|
|
2022
Q2 | $28K | Sell |
24,902
-2,719
| -10% | -$3.46K | ﹤0.01% | 6488 |
|
|
2022
Q1 | $56K | Buy |
27,621
+16,357
| +145% | +$38.9K | ﹤0.01% | 6394 |
|
|
2021
Q4 | $32K | Buy |
11,264
+5,494
| +95% | +$20.3K | ﹤0.01% | 7340 |
|
|
2021
Q3 | $25K | Sell |
5,770
-7,052
| -55% | -$31.5K | ﹤0.01% | 6941 |
|
|
2021
Q2 | $68K | Buy |
12,822
+8,319
| +185% | +$40K | ﹤0.01% | 6170 |
|
|
2021
Q1 | $21K | Sell |
4,503
-2,726
| -38% | -$12.4K | ﹤0.01% | 7353 |
|
|
2020
Q4 | $23K | Buy |
7,229
+1,483
| +26% | +$5.63K | ﹤0.01% | 6852 |
|
|
2020
Q3 | $20K | Buy |
5,746
+4,515
| +367% | +$16.6K | ﹤0.01% | 6321 |
|
|
2020
Q2 | $5K | Sell |
1,231
-16,849
| -93% | -$79.7K | ﹤0.01% | 7403 |
|
|
2020
Q1 | $69K | Sell |
18,080
-19,515
| -52% | -$90.7K | ﹤0.01% | 5577 |
|
|
2019
Q4 | $227K | Buy |
37,595
+2,642
| +8% | +$18.1K | ﹤0.01% | 5525 |
|
|
2019
Q3 | $264K | Sell |
34,953
-11,892
| -25% | -$134K | ﹤0.01% | 5037 |
|
|
2019
Q2 | $635K | Buy |
46,845
+39,121
| +506% | +$452K | ﹤0.01% | 4120 |
|
|
2019
Q1 | $42K | Sell |
7,724
-4,847
| -39% | -$23.6K | ﹤0.01% | 5695 |
|
|
2018
Q4 | $38K | Buy |
12,571
+6,990
| +125% | +$38.3K | ﹤0.01% | 6318 |
|
|
2018
Q3 | $46K | Buy |
5,581
+373
| +7% | +$2.86K | ﹤0.01% | 6229 |
|
|
2018
Q2 | $50K | Sell |
5,208
-2,225
| -30% | -$22.8K | ﹤0.01% | 5964 |
|
|
2018
Q1 | $64K | Sell |
7,433
-309
| -4% | -$3.33K | ﹤0.01% | 5540 |
|
|
2017
Q4 | $97K | Sell |
7,742
-2,493
| -24% | -$28.6K | ﹤0.01% | 5377 |
|
|
2017
Q3 | $86K | Sell |
10,235
-4,119
| -29% | -$43.5K | ﹤0.01% | 5406 |
|
|
2017
Q2 | $244K | Buy |
14,354
+10,457
| +268% | +$208K | ﹤0.01% | 4626 |
|
|
2017
Q1 | $78K | Sell |
3,897
-932
| -19% | -$18.5K | ﹤0.01% | 5221 |
|
|
2016
Q4 | $75K | Buy |
4,829
+3,829
| +383% | +$51.6K | ﹤0.01% | 5503 |
|
|
2016
Q3 | $13K | Buy |
+1,000
| New | +$9.5K | ﹤0.01% | 6618 |
|
|
2016
Q1 | – | Sell |
-4,311
| Closed | -$43K | – | 8343 |
|
|
2015
Q4 | $43K | Buy |
4,311
+2,482
| +136% | +$32.8K | ﹤0.01% | 5950 |
|
|
2015
Q3 | $27K | Buy |
+1,829
| New | +$44.9K | ﹤0.01% | 6414 |
|
UBS Group's ZYNE Position: Q4 2023 in Review
UBS Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 20,385 shares — an estimated $26K sold.
UBS Group first reported a position in ZYNE in Q3 2015 and held it in 31 quarters. The position peaked at $635K in Q2 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- UBS Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- UBS Group sold 20,385 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $26K.
- UBS Group first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 31 quarters.
- UBS Group's Zynerba Pharmaceuticals, Inc position peaked at $635K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.